Publications
Donbrow M., Benita S. and
Hoffman A. (1984). Microencapsulation of dichromate and paracetamol with Eudragit Retard polymers using phase separation by non-solvent addition. J. Appl. Biochem. Biotechn. 10:245-249.
Benita S.,
Hoffman A. and M. Donbrow M. (1985). Microencapsulation of paracetamol using polyacrylate resins (Eudragit Retard), kinetics of drug release and evaluation of kinetic model. J. Pharm. Pharmacol. 37:391-395.
Benita S.,
Hoffman A. and Donbrow M. (1985). Polyacrylate resin (Eudragit Retard) microcapsules as a controlled release drug delivery system: Improved non-solvent addition phase separation process. J. Microencapsulation 2:207-222.
Hoffman A., Donbrow M., Gross S.T., Benita S. and Bahat R. (1986). Fundamentals of release mechanism interpretation in multi-particulate systems: Determination of substrate release from single microcapsules and relation between individual and ensemble release kinetics. Int. J. Pharm. 29:195-211.
Gross S.T.,
Hoffman A., Donbrow M. and Benita S. (1986). Fundamentals of release mechanism interpretation in multiparticulate systems: The prediction of the commonly release equations from statistical population models for particle ensembles. Int. J. Pharm. 29:213-222.
Hoffman A., Donbrow M. and Benita S. (1986). Direct measurements on individual micro-capsule dissolution as a tool for determination of release mechanism. J. Pharm. Pharmacol. 38:764-766.
Donbrow M.,
Hoffman A. and Benita S. (1988). Variation of population release kinetics in polydisperse multiparticulate systems (microcapsules, microspheres, droplets, cells) with heterogeneity of one, two or three parameters in the population of individuals. J. Pharm. Pharmacol. 40:93-96.
Benita S., Babay D.,
Hoffman A. and Donbrow M. (1988). Relation between individual and ensemble release kinetics of indomethacin from microspheres. Pharm. Res. 5:178-182.
Babay D.,
Hoffman A. and Benita S. (1988). Design and release kinetic pattern evaluation of indomethacin microspheres intended for oral use. Biomaterials 9:482-488.
Hoffman A. and Levy G. (1989). Kinetics of drug action in disease states. XXIX. Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: Implications of severe hypoalbuminemia. J. Pharmacol. Exp. Ther. 249:117-122.
Hoffman A. and Levy G. (1989). Effect of enoxacin on theophylline neurotoxicity. Life Sci. 44:1803-1806.
Hoffman A. and Levy G. (1989). Gender differences in the pharmacodynamics of barbiturates in rats. Pharm. Res. 6:976-981.
Donbrow M.,
Hoffman A. and Benita S. (1990). Phase separation modulation and aggregation-prevention: Mechanism of the non-solvent addition in the presence and absence of polyisobutylene as an additive. J. Microencapsulation 7:1-15 (1990).
Hoffman A. and Levy G. (1990). Kinetics of drug action in disease states. XXXVI. Effect of cyclosporine on the pharmacodynamics and pharmacokinetics of a barbiturate (heptabarbital) in rats. J. Pharm. Sci. 79:19-22.
Hoffman A. and Levy G. (1990). Kinetics of drug action in disease states. XXXIX. Effect of orally administered activated charcoal on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline administered intravenously to rats with renal failure. Pharm. Res. 7:242-246.
Hoffman A. and Levy G. (1991). Kinetics of drug action in disease states. XL. Effect of dialyzable component(s) of uremic blood on theophylline neurotoxicity in rats. Pharm. Res. 8:415-417.
Backon J. and
Hoffman A. (1991). The lateral decubitus position may affect gastric emptying through an autonomic mechanism: the skin pressure-vegetative reflex. Br. J. Clin. Pharmacol. 32:138-139.
Hoffman A. (1992). Potential pharmacodynamic effect of charcoal on theophylline neurotoxicity in normal rats. Pharmacol. Biochem. Behav. 43:621-623.
Hoffman A. and Alfon J. (1992). High dose methotrexate does not affect the pharmacodynamics of phenobarbital hypnotic action but decreases the CNS sensitivity to pentylenetetrazol-induced maximal seizures in rats. Pharm. Res. 9:1295-1298.
Golomb G., Eitan Y. and
Hoffman A. (1992). Measurement of serum [3H] tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharm. Res. 9:1018-1023.
Hoffman A. and Baluom M. (1993). Effect of acute experimental liver dysfunction on the pharmacodynamics of heptabarbital in rats. Acta Anaesthesiol. Scand. 37:102-104.
Hoffman A. and Levy G. (1992). Kinetics of drug action in disease states XLI. Effect of adrenalectomy on the hypnotic activity of phenobarbital, the neurotoxicity of theophylline and pain sensitivity in rats. J. Pharmacol. Exp. Ther. 262:859-862.
Hoffman A., Klockowski P.M. and Levy G. (1993). Kinetics of drug action in disease states XLII. Effect of repeated blood sampling on the pharmacodynamics of phenobarbital in rats. J. Pharm. Sci. 82:229-230.
Breuer E., Golomb G.,
Hoffman A., Schlossman A., Van Gelder J.M., Saadeh H., Levi M. and Eitan Y. (1993). In vitro and in vivo inhibition of hydroxyapatite formation and dissolution by bisacylphosphonates and bishydroxyiminophosphonates. Phosphorus, Sulfur and Silicon. 76:167-170.
Drenger B., Sughayer H., Chrbasik J.,
Hoffman A., Goldovsky S. and Magora F. (1993). Dose-response effect of intrathecal alfentanil on canine lower urinary dynamics. Aneasth. Analg. 76:786-790.
Hoffman A. (1993). Chronopharmacodynamics of theophylline neurotoxicity in rats. J. Pharm. Sci. 82:668-669.
Golomb G., Avramoff A. andHoffman A. (1993). A new route of drug administration: intrauterine delivery of insulin and calcitonin. Pharm. Res. 10:828-833.
Hoffman A., Pinto E. and Gilhar D. (1993). Effect of pretreatment with anticonvulsants on theophylline-induced seizures in the rat. J. Crit. Care 8:1-6.
Hoffman A., Pinto E., Afargan M. and Schattner A. (1994). Cyclosporine enhances theophylline neurotoxicity in rats. J. Pharm. Sci. 84:559-561.
Hoffman A., Alfon J., Siegal Ts. and Siegal T. (1994). Pharmacodynamics of phenobarbital anaesthesia and pentylenetetrazol-induced maximal seizures in a rat model of neoplastic spinal cord compression. Pharm. Res. 11:536-540.
Hoffman A. and Habib G. (1994). Valproic acid intensifies the depressant action of phenobarbital and ethanol by a pharmacodynamic mechanism. J. Pharm. Sci. 83:733-735.
Hoffman A., Alfon J., Habib G., Pinto E. and Gorodetsky R. (1994). The effect of immunosuppression by total body irradiation on the pharmacodynamics of centrally acting drugs in rats. Pharm. Res. 11:704-708.
Hoffman A., Habib G., Gilhar D. and Zohar H. (1994). Cyclosporine increases the CNS sensitivity to the hypnotic effect of phenobarbital but not ethanol in rats. J. Pharm. Pharmacol. 46:760-764.
Hoffman A., Afargan, M., Pinto, E., Gilhar, D. and Backon, J. (1994). Differential effects of various anti-inflammatory drugs on theophylline neurotoxicity. Pharmacol. Biochem. Behav. 49:335-339.
Hoffman A., Fischer Y., Gilhar D. and Raz I. (1994). The effect of hyperglycaemia of glibenclamide in patients with non-insulin-dependent diabetes mellitus. Eur. J. Clin. Pharmacol. 47:53-55.
Hoffman A., Nyska A., Avramoff A. and Golomb G. (1994). Continuous versus pulsatile administration of erythropoietin (EPO) in anemic rats. Int. J. Pharm. 111:197-202.
Klang S.H., Frucht-Pery J.,
Hoffman A. and Benita S. (1994). Physico-chemical characterization and acute toxicity evaluation of a positively charged submicron emulsion vehicle. J. Pharm. Pharmacol. 46:986-993.
Raz I., Gilhar D. and
Hoffman A. (1994). Prolonged response to glibenclamide in NIDDM patients under normoglycemic state. Isr. Med. J. Sci. 30:775-778.
Hoffman A. and Goldberg, A. (1994). The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications. J. Pharmacokin. Biopharm. 22:449-468.
Donbrow M.,
Hoffman A., Benita S. (1995). Gradation of microcapsule wall porosity by deposition of polymer mixture (Eudragit RL and Eudragit RS): Phase separation of polymer mixtures and effects of external media and conditions on release. J. Microencapsulation 12:273-285.
Golomb, G., Shaked, I. and
Hoffman A. (1995). Intrauterine administration of peptide drugs for systemic effect. Adv. Drug. Deliv. Rev. 17:179-190. (Review)
Hoffman A., Shaked, I., Avramoff, A. and Golomb, G. (1995). Pharmacokinetics and pharmacodynamics of trans-endometrial administered peptides and macromolecules. Adv. Drug. Deliv. Rev. 17:191-203. (Review)
Shapira S.C., Chrubasik S.,
Hoffman A., Laufer N., Lewin A. and Magora F. (1996). Use of alfentanil for in vitro fertilization oocyte retrieval. J. Clin. Anesth. 8:282-285.
Golomb G., Van Gelder J.M., Alferiev I.S., Ornoy A.,
Hoffman A., Schlossman, A., Friedman-Ezra A., El-Hanany-Rosen N., Cohen R., Solomon V., Cohen, H., Rabinovich L. and Breuer E. (1996). Novel bisphosphonates for calcium-related disorders. Phosphorus, Sulfur and Silicon and Related Elements 109:221-224.
Hoffman A. (1996). Under-the-Counter (UTC) medications as a symptom of the malaise of the pharmacy profession. Pharm. Update 6:5-6. (Hebrew)
Katzhendler Y.,
Hoffman A., Goldberg A. and Friedman M. (1997). Modeling of drug release from erodible tablets. J. Pharm. Sci. 86:110-115.
Sevransky J.E., Shaked G., Novogrodsky A., Levitzki A., Gazit A.,
Hoffman A., Elin R.J., Quezado Z.M.N., Freeman B.D., Eichacker P.Q., Danner R.L., Banks S.M., Bacher J., Thomas M.L. III and Natanson C. (1997). Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine E. coli peritonitis. J. Clin. Invest. 99:1966-1973.
Hoffman A., Afargan M., Backon J. and Perlstein I. (1997). The anticonvulsant effect of deprenyl on pentylenetetrazol-induced seizures in Lewis rats. Intern. J. Neuroscience 90(3-4):223-232 (1997).
Hoffman A. and Ziv, E. (1997). Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin. Pharmacokinet. 33(4):285-301. (Review)
Hoffman A., Danenberg H.D., Katzhendler I., Shuval R., Gilhar D. and Friedman M. (1998). Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form. J. Control. Rel. 54:29-37.
Lomnicky Y., Friedman M., Luria M.H., Raz I. and
Hoffman A. (1998). The effect of mode of administration on the hypolipidaemic activity of niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid lowering efficacy in experimentally-induced hyperlipidemic rats. J. Pharm. Pharmacol. 50:1233-1239.
Hoffman A. (1998). Pharmacodynamic aspects of sustained release preparations. Adv. Drug Deliv. Rev. 33:185-199.
Hoffman A., Lomnicky Y., Luria M.H., Gilhar D. and Friedman M. (1999). Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug. Pharm. Res. 16:1093-1097.
Cohen H., Alferiev I.S., Monkonen J., Seibel M.J., Pinto T., Ezra A., Solomon V., Stepensky D., Sagi H., Ornoy A., Patlas N., Hagele G.,
Hoffman A., Breuer E. and Golomb G. (1999). Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio)ethylidene- 1,1-bisphosphonic acid betaine(isa-13-1) - a novel bisphosphonate. Pharm. Res. 16:1399-1406.
Hoffman A., Perlstein I., Habib G., Pinto E. and Gilhar D. (1999). The effect of cimetidine on the pharmacodynamics of theophylline-induced seizures and ethanol hypnotic activity. Pharmacol. Toxicol. 85:130-132.
Hoffman A. and Stepensky, D. (1999). Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit. Rev. Ther. Drug Carr. Syst. 16(6):571-639. (Review)
Ezra A.,
Hoffman A., Breuer E., Alferiev I.S., Monkkonen J., El Hanany-Rosen N., Weiss G., Stepensky D., Gati I., Cohen H. and Golomb G. (2000). A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem., 43: 3641-3652.
Shani, S., Morgenstin T. and
Hoffman A. (2000). Patients’ perception of drug therapy counseling in Israel. IMAJ. 2:438-441.
Perlstein I. and
Hoffman A. (2000). Cumulative plot of heart rate variability power spectrum assesses kinetics of action of cholinergic drugs in rats. Am J Physiol. Heart and Circulatory Physiology. 279:H110-H115.
Lomnicky Y., Haimov T., Luria M.H., Friedman M., and
Hoffman A. (2000). Pharmacodynamic effects of bezafibrate and niacin combination: Implications of the mode of administration. J. Pharm. Sci. 89:1046-1053.
Afargan M., Janson E.T., Gelerman G., Rosenfeld R., Ziv O., Karpov O., Wolf A., Bracha M., Shohat D., Liapakis G., Gilon C.,
Hoffman A., Stepensky D. and Oberg K. (2000). Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin. Endocrinology 142:477-486.
Hoffman A., Stepensky D., Ezra A., Van Gelder J.M. and Golomb G. (2001). Mode of administration - dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int. J. Pharm. 220:1-11.
Stepensky D., Friedman M., Srour W., Raz I. and
Hoffman A. (2001). Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J. Contr. Rel. 71:107-115.
Perlstein I., Stepensky D., Sapoznikov D. and
Hoffman A. (2001). Power spectral analysis of heart rate variability in rats as a quantitative tool in the PK-PD analysis of the parasympatholytic activity of atropine in rats. Pharm. Res. 18:1220-1225.
Mayan H., Bloom E. and
Hoffman A. (2002). Use of digoxin monitoring in a hospital setting as an essential tool in optimizing therapy. J. Pharm. Technol. 18:133-136.
Stepensky D., Golomb G. and
Hoffman A. (2002). Pharmacokinetic and pharmacodynamic evaluation of intermittent vs. continuous alendronate administration in rats. J. Pharm. Sci. 91:508-516.
Stepensky, D., Friedman, M., Raz, I. and
Hoffman A. (2002). PK-PD analysis of the glucose-lowering effect of metformin in diabetic rats reveals first pass PD effect. Drug Metab. Dispos. 30(8):861-868.
Perlstein, I., Stepensky, D., Kryzanski, W. and
Hoffman A. (2002). A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low dose scopolamine and atropine in rats. J. Pharm. Sci. 91(12):2500-2510.
Perlstein, I., Sapir, N., Backon, J., Sapoznikov, D., Karasik, R., Havlin, S. and
Hoffman A. (2002). Scaling vs. nonscaling methods of assessing autonomic tone in streptozotocin-induced diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 283(3):H1142-149.
Klausner, E.A., Lavy, E., Stepensky, D., Friedman, M. and
Hoffman A. (2002). Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res. 19:1516-1523.
Shavit O, Raz M, Chen M Blay A, Friedman N,
Hoffman A. (2002): An Economic Model for Cooperation Between a Not-for-profit HMO and a Pharmaceutical Company in a Disease Management Program: Transforming Conflict of Interests into Utility Maximization. Value in Health, 5(6): 467
Klausner, E.A., Eyal, S., Lavy, E., Friedman, M. and
Hoffman A. (2003). Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J. Control. Rel. 88(1):117-126.
Klausner, E.A., Lavy, E., Stepensky, D., Cserepes, E., Barta, M., Friedman, M. and Hoffman A. (2003). Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J. Clin. Pharmacol. 43(7):711-720.
Klausner, E.A., Lavy, E., Barta, M., Cserepes, E , Friedman, M.,
Hoffman A. (2003). Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res. 20(9):1466-1473.
Klausner, E.A., Lavy, E., Friedman, M. and
Hoffman A. (2003). Expandable gastroretentive dosage forms. J. Control. Release 90(2):143-162. (Review)
Stepensky, D., Kleinberg, L. and
Hoffman A. (2003). Bone as an effect compartment: models for uptake and release of drugs. Clin. Pharmacokinet. 42(10):863-881. (Review)
Hoffman A., Stepensky, D., Klausner, E.A., Lavy, E., Eyal, S. and Friedman, M. (2004). Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int. J. Pharm. 277:141-153. (invited paper)
Falk, R., Grunwald, J.,
Hoffman A., Domb, A.J. and Polacheck, I. (2004). Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue, and its therapeutic efficacy against murine aspergillosis. Antimicrob. Agents and Chemother. 48(9) 3606-3609.
Dahan, A. and
Hoffman A. (2005). Evaluation of chylomicrons flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 24(4): 381-388.
Perlstein, I., Burton, D.Y., Ryan, K., DeFelice, S., Simmers, E., Campbell, B., Connolly, J.M.,
Hoffman A. and Levy, R.J. (2005). Posttranslational control of a cardiac ion channel transgene in vivo: Clarithromycin-hMiRP1-Q9E interactions. Hum Gene Ther. 16(7):906-910.
Hess, S., Rotshild, V. and
Hoffman A. (2005). Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. Eur. J. Pharm. Sci. 25(2-3): 307-312.
Gershkovich, P. and
Hoffman A. (2005). Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. 26(5):394-404.
Bercovich, D., Friedlander, Y., Korem, S., Houminer, A.,
Hoffman A., Kleinberg, L., Shochat, D., Leitersdorf, E. and Meiner, V. (2006). The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis. 185(1):97-107.
Kagan, L., Lapidot, N., Afargan, M., Kirmayer, D., Moor, E., Mardor, Y., Friedman, M. and
Hoffman A. (2006). Gastroretentive accordion pill: Enhancement of riboflavin bioavailability in humans. J. Control. Release. 113(3):208-215.
Dahan, A. and
Hoffman A. (2006). Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm. Res. 23(9):2165-2174.
Dvir, E., Friedman, J.E., Lee, J.Y., Koh, J.Y., Younis, F., Raz, S., Shapiro, I.,
Hoffman A., Dahan, A., Rosenberg, G., Angel, I., Kozak, A. and Duvdevani, R. (2006). A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]butanoyl}-sn-glycero-3-phosophatidyl choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J. Pharmacol. Exp. Ther. 318(3):1248-1256.
Hoffman A. (2006). Prolonged-release ciprofloxacin: A viewpoint by Amnon
Hoffman, . J. Drug Deliv. 4(2):121-121. (Invited expert opinion).
Dahan, A. and
Hoffman A. (2007). Mode of administration-dependent brain uptake of indomethacin: sustained systemic input increases brain influx. Drug Metab. Dis. 35(2):321-324.
Gershkovich, P., Shteiner, D. and
Hoffman A. (2007).The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. Int. J. Pharm. 333(1-2):1-4.
Dahan, A. and
Hoffman A. (2007). The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in-vitro lipolysis and consecutive ex-vivo intestinal permeability data to predict in-vivo bioavailability in rats. Eur. J. Pharm. Biopharm.67(1):96-105.
Dahan, A., Duvdevani, R., Dvir, E., Elmann, A. and
Hoffman A. (2007). A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control. Release. 119(1):86-93.
Kagan, L., Gershkovich, P., Mendelman, A., Amsili, S., Ezov, N. and Hoffman A. (2007). The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur. J. Pharm. Biopharm. 67(3):759-765.
Gershkovich, P., Qadri, B., Yacovian, A., Amselem, S. and Hoffman A. (2007). Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur. J. Pharm. Sci. 31(5):298-305.
Szalat, A., Gershkovich, P., Ben-Ari, A., Shaish, A., Liberman, Y., Boutboul, E., Gotkine, M., Hoffman A., Harats, D., Leitersdorf, E. and Meiner, V. (2007) Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim. Biophys. Acta 1771(7):839-844.
Gershkovich, P. and Hoffman A. (2007). Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur. J. Pharm. Sci. 32(1):24-32.
Shavit, O., Leshno, M., Goldberger, A., Shmueli, A. and
Hoffman A. (2007). It's time to choose the study design! Net benefit analysis of alternative study designs to acquire information for evaluation of health technologies. Pharmacoeconomics 25(11):903-911. (Review)
Hess, S., Ovadia, O., Shalev, D., Senderovich, H., Qadri, B., Yehezkel, T., Salitra, Y., Sheynis, T., Jelinek, R., Gilon, C. and
Hoffman A. (2007). Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J. Med. Chem. 50(24):6201-6211.
Dahan, A., Mendelman A., Amsili, S., Ezov, N. and
Hoffman A. (2007). The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: comparison between anesthetized and freely moving conscious rat models. Eur. J. Pharm. Sci. 32(4-5):367-374.
Dahan, A., Duvdevani, R., Shapiro, I., Elmann, A., Finkelstein, E.,
Hoffman A. (2008). The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J. Control. Release. 126(1):1-9.
Lecht, S. Haroutiunian, S.,
Hoffman A. and Lazarovici, P. (2007). Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy. Ther. Clin. Risk Management. 3(3):467-474. (Review)
Chatterjee, J., Ovadia, O., Zahn, G., Marinelli, L.,
Hoffman A., Gilon, C. and Kessler, H. (2007). Multiple N-methylation by a designed approach enhances receptor selectivity. J. Med. Chem. 50(24):5878-5881.
Dvir, E., Elman, A., Simmons, D., Shapiro, I., Duvdevani, R., Dahan, A.,
Hoffman A. and Friedman, J.E. (2007). DP-155, a lecithin derivative of indomethacin, is a novel non steroidal anti-inflammatory drug for analgesia and Alzheimer’s disease therapy. CNS Drug Rev. 13(2):260-277. (Review)
Kagan, L. and
Hoffman A. (2008). Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv 5(6):681-692.
Hoffman A., Horwitz, E., Hess, S., Cohen-Poradosu, R., Kleinberg, L., Edelberg, A. and Shapiro, M. (2008). Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained-release delivery systems of antimicrobials. Pharm. Res. 25(3):667-671.
Kovo, M., Haroutiunian, S., Feldman, N.,
Hoffman A. and Glezerman, M. (2008). Determination of metformin transfer across the human placenta using dually perfused ex-vivo placental cotyledon model. Eur. J. Obstet. Gynecol. Repro. Biol 136(1):29-33.
Kagan, L. and
Hoffman A. (2008) Selection of drug candidates for gastroretentive dosage forms: Pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur. J. Pharm. Biopharm. 69(1):238-246.
Hoffman A., Qadri, B., Frant, J., Katz, Y., Bhusare, S., Breuer, E., Hadar, R. and Reich, R. (2008). Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor – synthesis, and pharmacodynamic and pharmacokinetic analysis. J. Med. Chem. 51(5):1406-1414. Erratum in: J. Med. Chem. 51:4357-4358.
Hess, S., Linde, Y., Ovadia, O., Safrai, E., Shalev, D., Swed, A., Halbfinger, E., Lapidot, T., Winkler, I., Gabinet, Y., Faier, A., Yarden, D., Portillo, F., Xiang, Z., Haskell-Luevano, C., Gilon, C. and
Hoffman A. (2008). Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J. Med. Chem. 51(4):1026-1034.
Biron, E., Chatterjee, J., Ovadia, O., Langenegger, D., Brueggen, J., Hoyer, D., Schmid, H.A., Jelinek, R., Gilon, C.,
Hoffman A. and Kessler, H. (2008). Improving oral bioavailability of peptides by multiple n-methylation: somatostatin analogs. Angewandte Chemie 47(14):2595-2599.
Kovo, M., Kogman, N., Ovadia, O., Nakash, I., Golan, A., and
Hoffman A. (2008). Carrier mediated transport of metformin across the human placenta determined by using the ex-vivo perfusion of the placental cotyledon model. Prenatal Diagnosis 28(6):544-548.
Mansur, N.,
Hoffman A., Weiss, A. and Beloosesky, Y. (2008). Continuity and adherence to chronic drug treatment of geriatric patients after hospital discharge. Drugs & Aging 25 (10)861-870.
Linde, Y., Ovadia, O., Safrai, E., Xiang, Z., Portillo, F.P., Shalev, D.E., Haskell-Luevano, C.,
Hoffman A. and Gilon, C. (2008). Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers: Peptide Science. 90:671-682.
Gruzman, A., Shamni, O., Ben Yakir, M., Sandovsky, D., Elgart, A., Alpert, E., Cohen, G.,
Hoffman A., Katzhendler, J., Cerasi, E., and Sasson, S. (2008). Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha. J. Med. Chem. 51(24):8096-8108.
Hoffman A. and Qadri, B. (2008). Eligen insulin - a system for the oral delivery of insulin for diabetes. IDrugs. (Investigational Drug Journal) 11(6):433-441. (Invited critical review)
Dahan, A. and
Hoffman A. (2008). Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J. Control. Release 129:1-10. (Review)
Chatterjee, J., Gilon, C.,
Hoffman A. and Kessler, H. (2008) N-Methylation of peptides: a new perspective in medicinal chemistry. Acc Chem. Res. 41:1331-1342. (Review)
Gershkovich, P., Fanous, J., Qadri B., Yacovan, A., Amselem, S. and
Hoffman A. (2009). The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. J. Pharm. Pharmacol. 61:31-39.
Ginosar, Y., Nadjari, M.,
Hoffman A., Firman, N., Davidson, E.M., Weiniger, C.F., Rosen, L., Weissman, C., Elchalal, U. and the ACET study group. (2009). Antepartum continuous epidural ropivacaine therapy reduces uterine artery vascular resistance in pre-eclampsia: a randomised, dose-ranging, placebo- controlled study. British J. Anaesth. 102:369-378.
Kagan, L., Lavy, E. andHoffman A. (2009). Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm Pharmacol Ther ;22(3):260-5.
Haroutiunian, S., Ratz Y., Rabinovich B, Adam M and
Hoffman A. (2009). Valproic acid plasma concentration decrease in a dose-independent manner following administration of meropenem: a retrospective study. J. Clin. Pharmacol. 49(11):1363-9.
Kagan, L. and
Hoffman A., (2009) Biopharmaceutical aspects of gastro-retentive dosage forms: The gabapentin paradigm JDDST 19(4):233-9.
Gershkovich, P., Itin, C., Yacovan, A., Amselem, S. and
Hoffman A. (2009) Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. Translational Research ;153(6):296-300.
Haroutiunian, S. Lecht, S. Zur, AA.
Hoffman A. and Davidson E. (2009) Managing postherpetic neuralgia (PHN) in Myasthenia Gravis patients - a challenge for pain pharmacotherapy. J Pain Palliat Care Pharmacother. 23(3):242-60.
Chatterjee J, Ovadia O, Zahn G, Marinelli L,
Hoffman A. Gilon C, Kessler H. Highly selective cyclic hexapeptides antagonist of GPIIb-IIIa by multiple N-methylation Adv Exp Med Biol. 2009;611:209-10.
Chatterjee J, Ovadia O, Gilon C,
Hoffman A. Mierke D, Kessler H. (2009) N-methylated cyclic pentapeptides as template structures. Adv Exp Med Biol.;611:109-10.
Haroutiunian S., Yifrah I.,
Hoffman A. (2009) Comparison of intravenous, epidural and intrathecal administration of methadone in a rat model. The Journal of Pain 10 (4) S54
Swed A., Eyal, S., Madar, I., Zohar-Kontante, H., Weiss, L.,
Hoffman A. (2009) The role of P-Glycoprotein in Intestinal Transport versus the BBB Transport of Tetraphenylphosphonium (TPP)" Mol Pharm;6(6):1883-90.
Ovadia, O., Linde, Y., Haskell-Luevano, C., Dirain M.L., Sheynis T., Jelinek R., Gilon, C and
Hoffman A. (2010). The Effect of Backbone Cyclization on PK/PD Properties of Bioactive Peptide-Peptoid Hybrids: The Melanocortin Agonist Paradigm. Bioorganic and Medicinal Chemistry 15;18(2):580-9.
Dahan A., Miller J.,
Hoffman A., Amidon G. and Amidon G., (2010) The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: Mechanistic modeling and application to progesterone. J. Pharm Sci. 99(6):2739-49.
Kagan L., Dreifinger T., Mager D. and
Hoffman A. (2010) Role of P-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Met. Dispos 38(9):1560-6.
Ovadia, O., Greenberg S., Laufer B., Gilon C.,
Hoffman A. and Kessler H. (2010) Improving of drug like properties of peptides: the somatostatin paradigm. Expert Opin. Drug. Discov. 5(7): 1-17.
Elgart, A., Farber, S., Domb, A., Polacheck, I. and
Hoffman A. (2010) Polysaccharide pharmacokinetics: Amphotericin B arabinogalactan conjugate – a drug delivery system or a new pharmaceutical entity?" Biomacromolecules 9;11(8):1972-7.
Hurevich M, Swed A, Joubran S, Cohen S, Freeman NS, Britan-Rosich E, Briant-Longuet L, Bardy M, Devaux C, Kotler M,
Hoffman A. Gilon C. (2010) Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigm. Bioorg Med Chem. 18(15):5754-61.
Horwitz E., Kagan L., Avni-Magen N., Daryi D., Gati I.,
Hoffman A., Friedman M., and Lavy, E., (2011) A Novel Subcutaneous Controlled-release Amoxicillin Degradable Implant for Extended-interval Administration in Veterinary Medicine. J. Vet. Pharmacol. Therap 34, 494–498
Horwitz, E., Kagan, L., Chamisha, Y., Gati., I.,
Hoffman A., Friedman, M., and Lavy, E., (2011) Novel Gastro-retentive Controlled-release Drug Delivery System for Amoxicillin Therapy in Veterinary Medicine. J. Vet. Pharmacol. Therap 34: 487–493
Kovo, M., Golan A., Wainstein, J., Matas, Z., Haroutiunian, S.,
Hoffman A. and Golan A (2011) Placental transfer of the insulin analog Glargine in the ex vivo perfused placental cotyledon model. Endocr Res. 31(1); 19-24.
Frant, J., Veerendhar, A., Chernilovsky, T., Nedvetzki, S., Vaksman, O.,
Hoffman A., Breuer, E., Reich, R. (2011) Carbamoylphosphonates 9 - Orally active, antimetastatic, non-toxic, diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors. Chem. Med. Chem. 6(8):1471-7.
Gruzman A, Elgart A, Viskind O, Billauer H, Dotan S, Cohen G, Mishani E,
Hoffman A. Cerasi E, Sasson S (2011) Antihyperglycaemic activity of 2,4:3,5-dibenzylidene-D-xylose-dithioacetal in diabetic mice. J Cell Mol Med. May 12. doi: 10.1111/j.1582-4934.2011.01340.
Ovadia O., Greenberg S., Chatterjee J., Laufer B., Opperer F., Kessler H., Gilon C.,
Hoffman A.. (2011) The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm. 8(2):479-87
Horwitz, E., Tal-Gan, Y., Temper V., Shapiro,M., Gilon, M., and
Hoffman A. (2012) Chemical Trapping of Vancomycin: A potential strategy for preventing selection of vancomycin-resistant Enterococci. Microbial Drug Resistance 18(2):109-15
Avramoff A., Khan W., Ezra A., Elgart A.,
Hoffman A. and Domb AJ (2012) Cyclosporin pro-dispersion liposphere formulation. J. Control. Release 160(2):401-6.
Bollinger M., Manzenrieder F., Kolb R., Bochen, A., Neubauer S., Marinelli L., Limongelli V., Novellino Ettore; Moessmer, Georg; Pell, Reinhard; Lindner, W., Fanous J.,
Hoffman A., and Kessler, H., (2012) Ttailoring of integrin ligands: probing the charge capability of the metal-ion-dependent adhesion site J Med. Chem. 26;55(2):871-82.
Naveh S., Tal-Gan Y., Ling S.,
Hoffman A., Holoshitz J., and Gilon C., (2012) Developing potent backbone cyclic peptides bearing the shared epitope sequence as rheumatoid arthritis drug-leads. Bioorganic & Medicinal Chemistry Letters, 22(1): 493-496
Elgart A., Cherniakov I., Aldouby Y., Domb A andHoffman A.(2012) Lipospheres and Pro-Nano Lipospheres for Delivery of Poorly Water Soluble Compounds. Chemistry and Physics of Lipid 165(4):438-453
Horwitz, E., Shavit O., Shuoval R., Moses A., Shapiro M.,
Hoffman A.(2012) Evaluating real-life clinical and economic burden of amphotericin-B deoxycholate adverse reactions. International Journal of Clinical Pharmacy 34(4):611-617.
Beck, J., Chatterjee, J., Laufer, B ., Marelli, U., Kiran. F. A., Neubauer, S., Ovadia, O., Greenberg, S., Gilon, C.,
Hoffman A., Kessler, H. (2012) Intestinal permeability of cyclic peptides: Common key backbone motifs identified. Journal of the American Chemical Society (JACS) 25;134(29):12125-33..
Breuer,E., Reich, R.,
Hoffman A., Veerendhar, A., Maresca A., Innocenti A., and Supuran C.T. (2012) Carbamoylphosphonates Control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. J. Med. Chem., 13;55(17):7875-82.
Burshtein G., Greenberg. S., Friedman, M., and
Hoffman A., (2013) Transepithelial transport of a natural cholinesterase inhibitor, Huperzine A, along the gastrointestinal tract: the role of ionization on absorption mechanism. Planta Medica. 79:259-265
Levi I, Eskira Y, Eisenstein M, Gilon C,
Hoffman A. Talgan Y, Fanous J, Bersudsky Y, Belmaker R, Agam G, Almog O. (2013) The Calbindin-D28k binding site on inositol monophosphatase may allow inhibition independent of the lithium site of action. European Neuropsychopharmacology. 23(12):1806-15.
Elgart A., Cherniakov I., Aldouby Y., Domb A J and
Hoffman A.(2013) Improved Oral Bioavailability of BCS Class 2 Compounds by Self Nano-Emulsifying Drug Delivery Systems (SNEDDS): the Underlying Mechanisms for Amiodarone and Talinolol. Pharm. Res. 30(12):3029-44
Ickowicz DE, Farber S, Sionov E, Kagan S,
Hoffman A. Polacheck I, Domb A J. (2014) Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide. Biomacromolecules. 9;15(6):2079-89
Reich R,
Hoffman A., Suresh, R. R., Shai, O., Frant, J., Maresca, A., Supuran, C., Breuer, E. (2015) Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo. J Enzyme Inhib Med Chem 11:1-6.
Cherniakov I, Domb A J and
Hoffman A. (2015) R1 Self Nano-Emulsifying Drug Delivery Systems (SNEDDs): an Update of the Biopharmaceutical Aspects. Expert Opin. Drug Deliv. 5:1-13
Fanous J, Swed A, Joubran S, Hurevich M, Britan-Rosich E, Kotler M, Gilon C,
Hoffman A. (2015) Superiority of the S,S conformation in diverse pharmacological processes: Intestinal transport and entry inhibition activity of novel anti-HIV drug lead. Int. J. Pharm. 30;495(2):660-3.
Marelli UK, Ovadia O, Frank AO, Chatterjee J, Gilon C,
Hoffman A. Kessler H. (2015) cis-Peptide Bonds: A Key for Intestinal Permeability of Peptides?. Chemistry. 19;21(43):15148-52
Valitsky M,
Hoffman A. Unterman T, Bar-Tana J. (2016) Insulin Sensitizer Prevents and Ameliorates Experimental Type-1 Diabetes. Am J Physiol Endocrinol Metab. doi: 10.1152/ajpendo.00329.2016.
Cherniakov I, Izgelov D, Domb AJ,
Hoffman A. (2017) The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancerson the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci. 20;109:21-30. doi: 10.1016/j.ejps.2017.07.003
Cherniakov I, Izgelov D, Barasch, D; Davidson E. Domb AJ,
Hoffman A. (2017) Piperine-Pro-Nanolipospheres as a Novel Oral Delivery System of Cannabinoids: Pharmacokinetic evaluation in Healthy Volunteers in Comparison to Buccal Spray Administration" 8;266:1-7 J Cont. Rel
Kessler H, Weinmüller M, Rechenmacher F, Kiran Marelli U, Reichart F, Kapp TG, Räder AB, Di Leva FS, Marinelli L, Novellino E, Muñoz Félix JM, Hodivala-Dilke K, Schumacher A, Fanous J, Gilon C,
Hoffman A. (2017) Overcoming the lack of oral availability of cyclic hexapeptides: Design of a new selective and orally available ligand for the integrin αvβ3. Angew Chem Int Ed Engl. 56, 1 – 6
Atsmon J., Cherniakov I., Izgelov D.,
Hoffman A., Domb A.J., Deutsch L., Deutsch F., Heffetz D. and Sacks H. (2018) PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers. J Pharm Sci. 107(5):1423-1429
Bitton R., Tsuriel M., Suresh R., Breuer E., Reich R. and
Hoffman A. (2018) Investigation of Intestinal Absorption Enhancers: Individual vs. Blends with the Carbamoylphosphonate JS403. J Bioequiv Availab 10:0-2 DOI: 10.4172/0975-0851.1000372
Izgelov, D., Cherniakov, I., Aldouby Bier, G., Domb, A J;
Hoffman A. (2018) The effect of piperine pro-nano lipospheres on direct intestinal phase II metabolism: the raloxifene paradigm of enhanced oral bioavailability. Mol. Pharm. 15(4):1548-1555
Dishon S, Shumacher A, Fanous J, Talhami A, Kassis I, Karussis D, Gilon C,
Hoffman A. and Nussbaum G (2018) Development of a Novel Backbone Cyclic Peptide Inhibitor of the Innate Immune TLR/IL1R Signaling Protein MyD88. Sci. Rep. 8(1):9476.
Schumacher-Klinger, A; Fanous, J; Merzbach, S; Weinmueller, M; Reichart, F; Räder, A; Gitlin-Domaglaska, A; Gilon, C; Kessler, H;
Hoffman A. (2018) Enhancing oral bioavailability of cyclic RGD hexa-peptides by the Lipophilic Prodrug Charge Masking approach: Redirection of peptide intestinal permeability from paracellular to transcellular pathway. Mol. Pharm. 6;15(8):3468-3477
Räder AFB, Weinmüller M, Reichart F, Schumacher-Klinger A, Merzbach S, Gilon C,
Hoffman A. Kessler H. (2018) Orally Active Peptides: Is There a Magic Bullet? Angew Chem Int Ed Engl. 57(44):14414-14438.
Shmoeli E., Izgelov D.,
Hoffman A. and Domb A.J. (2018) Pro-nanoliposphers (PNL) for improved oral bioavailability of insoluble drugs. Am. J Pharmacol Pharmacother DOI: 10.21767/2393-8862-C1-003
Dishon S, Schumacher-Klinger A, Gilon C,
Hoffman A. Nussbaum G.(2019), Myristoylation Confers Oral Bioavailability and Improves the Bioactivity of c(MyD 4-4), a Cyclic Peptide Inhibitor of MyD88. Mol Pharm. DOI:1.10.1021/acs.molpharmaceut.8b01180.
Books Edited
Hoffman A. "Pharmacodynamic Aspects of Drug Delivery". Invited Theme Issue Editor within the journal of Adv. Drug Deliv. Rev., Vol. 33, Tomlinson, E., Hirota, S., Lee, V.H.L., Pouton, C.W., Eds.-in-Chief (1998).
Chapters
Hoffman A., Pharmacodynamic interactions between cyclosporin and CNS acting drugs. In: Progress in Clinical Pharmacy: Optimizing the Pharmacotherapy Process. Luscombe DK, Hudsson MC, and Caramona M. Eds, European Society of Clinical Pharmacy, Leiden The Netherlands, 1997, pp. 63-67.
Hoffman A., Theme Issue on "Pharmacodynamic Aspects of Drug Delivery". Ed. Adv. Drug Deliv. Rev., (Preface), 1998, 33:183-184. Invited Theme Issue Editor.
Hoffman A., The use of bezafibrate in the treatment of hyperlipidemia. Professional Opinion – Cardiac Risk Factors, issue 3, Bridgett Communications. 2000. Invited Review.
Cass, Y. and
Hoffman A., Clinical Pharmacy in Israel, In: Clinical Pharmacy in Europe, Carstensen G. Ed. European Society of Clinical Pharmacy, Leiden, The Netherlands, 2000.
Hoffman A., Pharmacokinetic and pharmacodynamic aspects of gastroretentive and controlled release dosage forms. In: Optimization of oral drug delivery systems: Getting the best from your drugs. Capsugel Library, Basel, Switzerland 2002. pp.75-86.
Dahan, A. and
Hoffman A., Enhanced gastrointestinal absorption of lipophilic drug. In: Enhancement in Drug Delivery, Touitou, E. and Barry, B., Eds., CRC Press (Taylor & Francis Group), Boca Raton-London-New York, 2006, pp. 111-131.
Kadri, B. and
Hoffman A., Gastro-retentive systems. In: Encyclopedia of Pharmaceutical Technology 3rd Ed. Swarbrick, J., Ed.Taylor & Francis Books, New York, NY, 2006.
Gershkovich, P., Kagan, L. and
Hoffman A., Lymphatic absorption of nanoparticles. In: Nanoparticles for Pharmaceutical Applications, Domb, A.J., Tabata, Y., Kumar, M.N.V.R., Farber, S., Eds, American Scientific Publishers, Stevenson Ranch, California, 2007, pp. 167-175.
Patents
Benita, S., Donbrow, M. and
Hoffman A.: Microencapsulation by means of a cold non-solvent mixing method. Israeli Patent, 63714 (1981).
Donbrow, M., Benita, S. and
Hoffman A.: Production of microcapsules. Israeli Patent Application 7O431 (1984).
Hoffman A., Golomb, G. and Avramoff, A.: Administration of drugs to female mammals for systemic effect. Israeli Patent application no. 101673 (1992).
Hoffman A. and Afargan, M.: A pharmaceutical composition containing deprenyl. Israeli Patent application no. 107593 (1993).
Hoffman A., Golomb, G. and Avramoff, A.: Compositions and devices for the intrauterine administration of drugs. International application. The Patent Cooperation Treaty (PCT) no. WO 93/20797.
Hoffman A., Katzhendler, Y. and Friedman, M.: Controlled release pharmaceutical preparations, Israeli Patent application no. 115857 (1995).
Hoffman A., Katzhendler, Y. and Friedman, M.: Pharmaceutical preparations for controlled release of beta-lactam antibiotics. PCT/IL97/00368 (1997).
Lomnicky, Y. Friedman, M. and
Hoffman A.: Controlled-release oral delivery system of drugs having presystemic biophase. Israeli Patent application no. 125780 (1998).
Hoffman A., Klausner, E., Lavy, E. and Friedman, M.: Gastroretentive drug delivery system. Israeli Patent application, no. 133196 (1999).
Hoffman A., Klausner, E., Lavy, E. and Friedman, M.: Gastroretentive controlled release pharmaceutical dosage form. PCT/IL00/00774 (2000).
Friedman, M., Klausner, E., Lavy, E. and
Hoffman A.: Gastroretentive controlled release pharmaceutical dosage forms, International Application WO0137812, (May 31, 2001).
Katzhendler, I.Y.,
Hoffman A. and Friedman, M.: Pharmaceutical preparations for the controlled release of beta-lactam antibiotics. US 6,399,086 B1 (2002).
Hoffman A.PI, Lavy, E.PI, Klausner, E.S, Friedman, M.PI: Gastroretentive controlled release pharmaceutical dosage forms. US Pat No 6685962 (2004).
Gilon, C.,
Hoffman A. , Linda, Y., and Hess, S.: Oral available peptidomimetic Melanocortin-4 receptor agonist PCT/IL2006/000640: WO 2006/129317 (December 7, 2006).
Afargan, M., Kirmayer, D., Lapidot, N., Friedman, M.,
Hoffman A.: Gastro-retentive diagnostic assemblies. International Application WO 2006/072948. PCT/IL2006/000017. (January 5, 2006).
Hoffman A.PI, Gilon, C.PI, Ovadia, O.S and Linda, Y.S: The Trident Motif: a novel mechanism to improve cell and membrane permeability. Israeli Patent application (2007).
Hoffman A., Domb, A. and Gershkovich, P: Orally Available apomorphine Lipophilic Prodrugs and Derivatives. US provisional patent application No 60/935,689 on (filed on 27/08/2007).
Breuer, E, Reich, R, Frant, J. and
Hoffman A.: Novel carbamoylphosphonates as high affinity MMP inhibitors. Israeli Patent application (2008)
Hoffman A. Swed, A., and Gilon C. Orally available CCK-8 analog for the treatment of diabetes and metabolic diseases. Israeli Patent application (2008)
Hoffman A. Swed, A., Haroutiunian, S, and Gilon C. Orally available backbone cyclic peptide derivatives of endorphins for pain management. Israeli Patent application (2008)
Hoffman A., Lavy, E., Friedman, M. A gastroretentive dosage form for oral treatment of domestic animals PCT/IL2010/000724 (2011)
Gilon C.
Hoffman A.Hurevich M., Swed, A., Jubran,S. and Kotler, M.: Novel macrocyclic molecules for treating or preventing HIV infection Israeli Patent application (2008)
Friedman M.Hoffman A. Burshtein G. Oral sustained release formulation of huperzine a. Israeli Patent application (2009); PCT IB2011/051721 (2011)
Almog O., Eskira Y., Bersudskyb, Y.,Tal-Gane Y., Ovadiad, O., Agam, G.,
Hoffman A., Gilon, C., Synthetic peptides Interefering with binding of calbindin-D28k to inositol monophosphatase-1 for the treatment of mood disorders. Israeli Patent application (2010); PCT (2011).
Hoffman A., Elgert A. Solodkin I., Domb, A: Pro-nanodispersion liquid formulations for improved bioavailability and advanced biodistribution Provisional US application number 61/615,457 filed March 26 2012–06–19
Hoffman A., Lavy, E., Friedman, M.:Sustained-release injectable formulation WO 2012131678 A1 (2012) US 20140018323 A1 (2014)
Hoffman A., Elgert A. Cherniakov I., Domb, AJ: Formulation and method for increasing oral bioavailability of drugs WO 2013108254 A1 (2013); 11/27/14 - 20140348926
Breuer, E, Reich, R, Frant, J. and
Hoffman A., Novel carbamoylphosphonates inhibitors and uses thereof. PCT/IL2010000115 : United States Patent Application No. 13/148,421 (2014).
Holoshitz, J. Song, L., Gilon C.,
Hoffman A., Methods and compositions for the treatment of bone remodeling disorders WO 2014130949 A1 2014
Holoshitz, J., Ling, S., Xiujun P. , de Almeida D., Gilon C.,
Hoffman A., Compositions and methods for inducing an immune response US. Patent number 9555086 January 31, 2017
C. Gilon, A. Klinger, J. Naoum,
Hoffman A., Oral Bioavailable Somatostatin Derivatives And Methods For Producing, U.S. Provisional Patent Application No. 62/560,216 (2017)
H. Kessler, M. Weinmüller, F. Rechenmacher,
Hoffman A. Gilon C., Fanous J., Klinger A., Orally Available RGD containing peptidomimetics BayPAT: B77132 EP (2017)
Hoffman A., Gilon C., Fanous J., Klinger A., The Lipophilic Prodrug Charge Masking (LPCM) Method for the Enhancement of Oral Bioavailability of Charged Peptides and peptidomimetics U.S. Provisional Patent Application No. 62/560,217 (2017)
Domb AJ., Hoffman A., Izaglov D., Cherniakov I., "Formulation and method for increasing oral bioavailability of drugs" United States Patent Application No. 14/371,819 (2017)
Hoffman A., Lavy E., Friedman M., Nudelman Z., Kirmayer D., "Florfenicol compositions for single-injection treatment". Provisional patent application (September 6th) 62/727,574 (2018)
Domb AJ., Hoffman A., Izgelov D., Novel cannabinoid formulations US Patent App. 15/770,905, 2018
Bar Shavit R., Gilon C., Hoffman A. ”PAR4 Derived Peptides, Nalogs And Uses Thereof” U.S. Provisional Patent Application No. 62/808,325 filed on February 21, 2019
